Patent AT191081B successfully refreshed from Google Patents.
Patent US4692452A successfully refreshed from Google Patents.
US4692452A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for treatment of endometritis in mammalian females
Assignee: Spofa Spojene Podniky Pro Zdravotnickou Vyrobu
•
Filing: 1986-06-12
•
Granted: 1987-09-08
•
Expires: 2006-06-12
Abstract
Abstract This invention relates to a method for the treatment of endometritis (chronic and/or acute puerperal inflammations) in mammalian females comprising the administration of 1-(8-alpha-ergolinyl)-3,3-diethylurea derivatives of Formula I ##STR1## in which R 1 represents an alkyl group containing 1 to 3 carbon atoms, R 2 represents a hydrogen atom or an alkyl group containing 1 to 3 carbon atoms, and X represents a hydrogen atom or a double bond between the carbon atoms at positions 9 and 10. The compound according to Formula I, or a pharmaceutically acceptable acid addition salt thereof, is the physiologically active component of the therapeutic composition and method. The compound may be combined with a pharmaceutically acceptable diluent, vehicle, excipient, auxiliary, or carrier. The invention is particularly advantageous in veterinary medicine, when applied to the treatment of farm animals, such a cows.
Inventors
- 👤 Antonin Cerny
- 👤 Jiri Krepelka
- 👤 Karel Rezabek
- 👤 Maria Fruhaufova
- 👤 Milan Pesak
- 👤 Bohumil Sevcik
- 👤 Josef Kral
- 👤 Antonin Borovicka
- 👤 Petr Bilek
- 👤 Dagmar Picmausova
- 👤 Josef Stuchlik
- 👤 Josef Picha
- 👤 Jana Strakova
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 13:50
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/47; A61K31/48; A61P; A61P13/00; A61P13/02; A61P15/00
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
97 words
A method for the treatment of endometritis in mammalian females in need of said treatment comprising the administration to said mammalian female of an effective amount for treating endometritis of 1-(8-alpha-ergolinyl)-3,3-diethylurea derivative or a pharmaceutically acceptable acid addition salt thereof of Formula I ##STR4## wherein R 1 is alkyl having from 1 to 3 carbon atoms, R 2 is selected from the group consisting of hydrogen and alkyl having 1 to 3 carbon atoms, and X is selected from the group consisting of hydrogen and a double bond between the carbon atoms at positions 9 and 10.
Claim 2
Independent Claim
97 words
A method for the treatment of endometritis in mammalian females in need of said treatment comprising the administration to said mammalian female of an effective amount for treating endometritis of 1-(8-alpha-ergolinyl)-3,3-diethylurea derivative or a pharmaceutically acceptable acid addition salt thereof of Formula I ##STR4## wherein R 1 is alkyl having from 1 to 3 carbon atoms, R 2 is selected from the group consisting of hydrogen and alkyl having 1 to 3 carbon atoms, and X is selected from the group consisting of hydrogen and a double bond between the carbon atoms at positions 9 and 10.
Claim 3
Independent Claim
51 words
A method for the treatment of endometritis in mammalian females in need of said treatment comprising the administration to said mammalian female of an effective amount for treating endometritis of a compound selected from the group consisting of 1-[(5R,8S,10R)-6-methyl-8-ergolinyl]-3,3-diethylurea, 1-(5R,8S)-6-methyl-9,10-dihydro-8-ergolinyl)-3,3-diethylurea, 1-(5R,8S,10R)-6-propyl-8-ergolinyl)-3,3-diethylurea, and 1-(5R,8S,10R)-1-methyl-6-propyl-8-ergolinyl)-3,3-diethylurea or a pharmaceutically acceptable acid addition salt thereof.
Claim 4
Independent Claim
51 words
A method for the treatment of endometritis in mammalian females in need of said treatment comprising the administration to said mammalian female of an effective amount for treating endometritis of a compound selected from the group consisting of 1-[(5R,8S,10R)-6-methyl-8-ergolinyl]-3,3-diethylurea, 1-(5R,8S)-6-methyl-9,10-dihydro-8-ergolinyl)-3,3-diethylurea, 1-(5R,8S,10R)-6-propyl-8-ergolinyl)-3,3-diethylurea, and 1-(5R,8S,10R)-1-methyl-6-propyl-8-ergolinyl)-3,3-diethylurea or a pharmaceutically acceptable acid addition salt thereof.
Claim 5
Dependent Claim
45 words
A method according to claim 1 wherein the compound according to Formula I is administered in the form of a pharmaceutically acceptable acid addition salt, with the acid selected from the group consisting of hydrochloric, hydrobromic, phosphoric, acetic, maleic, tartaric, citric, terebic, and methanesulfonic acid.
Claim 6
Dependent Claim
41 words
A method according to claim 2 wherein the compound is administered in the form of a pharmaceutically acceptable acid addition salt, with the acid selected from the group consisting of hydrochloric, hydrobromic, phosphoric, acetic, maleic, tartaric, citric, terebic, and methanesulfonic acid.
Claim 7
Independent Claim
119 words
A method for the treatment of endometritis in mammalian females in need of said treatment comprising the administration to said mammalian female of about 0.05 mg/kg of a 1-(8-alpha-ergolinyl)-3,3-diethylurea derivative of Formula I ##STR5## wherein R 1 is alkyl having from 1 to 3 carbon atoms, R 2 is selected from the group consisting of hydrogen and alkyl having 1 to 3 carbon atoms, and X is selected from the group consisting of hydrogen and a double bond between the carbon atoms at positions 9 and 10, said derivative being administered in the form of an acid addition salt with an acid selected from the group consisting of hydrochloric, hydrobromic, phosphoric, acetic, maleic, tartaric, citric, terebic, and methanesulfonic acid.
Claim 8
Independent Claim
119 words
A method for the treatment of endometritis in mammalian females in need of said treatment comprising the administration to said mammalian female of about 0.05 mg/kg of a 1-(8-alpha-ergolinyl)-3,3-diethylurea derivative of Formula I ##STR5## wherein R 1 is alkyl having from 1 to 3 carbon atoms, R 2 is selected from the group consisting of hydrogen and alkyl having 1 to 3 carbon atoms, and X is selected from the group consisting of hydrogen and a double bond between the carbon atoms at positions 9 and 10, said derivative being administered in the form of an acid addition salt with an acid selected from the group consisting of hydrochloric, hydrobromic, phosphoric, acetic, maleic, tartaric, citric, terebic, and methanesulfonic acid.
Claim 9
Independent Claim
62 words
A method for the treatment of endometritis in mammalian females in need of said treatment comprising the steps of administering to said mammalian female a first dose of a solution containing 20 mg of 1-(5R,8S,10R)-6-methyl-8-ergolinyl)-3,3-diethylurea dihydrogen citrate by intramuscular injection, and administering to said mammalian female a second identical dose within from 2 to 10 days following the first administration, as needed.
Claim 10
Independent Claim
62 words
A method for the treatment of endometritis in mammalian females in need of said treatment comprising the steps of administering to said mammalian female a first dose of a solution containing 20 mg of 1-(5R,8S,10R)-6-methyl-8-ergolinyl)-3,3-diethylurea dihydrogen citrate by intramuscular injection, and administering to said mammalian female a second identical dose within from 2 to 10 days following the first administration, as needed.
References Cited (Backward Citations)
US3251846A
Cited
GB950528A
Cited
GB1174617A
Cited
US3954988A
Cited
DE2523026A1
Cited
US4045562A
Cited
US4096266A
Cited
US4379790A
Cited
US4522820A
Cited
GB2116548A
Cited
DE3410218A1
Cited
US4593032A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-09-07 | 1991-03-09 | 1991-09-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-09-07 | 1995-03-09 | 1995-09-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-09-07 | 1999-03-09 | 1999-09-08 | $7700.00 | Window Closed / Lapsed |